58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial)

January 31, 2022
https://clinicaltrials.gov/ct2/show/NCT04760769
Parkinson Disease
Principal Investigator: Peter A Le Witt, MD
Parkinson disease
Open
248-661-6270